Tay-Sachs Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major Tay-Sachs disease markets are expected to exhibit a CAGR of 4.56% during 2024-20324.
The Tay-Sachs disease market has been comprehensively analyzed in IMARC's new report titled "Tay-Sachs Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Tay-Sachs disease refers to a rare genetic disorder that primarily affects the nervous system. It is caused by a deficiency in the hexosaminidase A enzyme, which leads to the accumulation of a fatty substance called GM2 ganglioside in the nerve cells of the spinal cord and brain. The symptoms of this condition typically appear in the first few months of life and progress rapidly. Infants suffering from Tay-Sachs disease may experience developmental delays, progressive weakness, loss of muscle tone, an exaggerated startle response to sudden noises, an inability to move their eyes, etc. Numerous other common indications of the ailment may include seizures, difficulty swallowing, and, eventually, a loss of vision and hearing. The diagnosis of this illness requires a combination of the patient's clinical features, medical and family history, along with a physical and eye examination. A healthcare provider may also perform genetic testing to determine changes in the genome responsible for underlying symptoms. Furthermore, several blood workups to check the hexosaminidase A enzyme levels in the blood are recommended.
The rising incidences of DNA alterations, gene abnormalities, and chromosomal damage due to inherited disorders are primarily driving the Tay-Sachs disease market. Moreover, the widespread adoption of effective drugs, such as anti-seizures and antibiotics, to ease the symptoms and prevent the progression of the ailment is also augmenting the market growth. Apart from this, the inflating utilization of prenatal testing for Tay-Sachs disease through chorionic villi sampling or amniocentesis, which can reveal gene mutations associated with the condition and facilitate early detection in patients, is further creating a positive outlook for the market. Additionally, the escalating demand for occupational and physical therapies, owing to their numerous benefits like maintained joint flexibility, enhanced range of motion, delayed loss of muscular functions, improved daily activities, etc., is acting as another significant growth-inducing factor. Besides this, the growing popularity of gene therapy, that aims at permanent correction of the genetic defect, thereby allowing more effective and long-lasting therapeutic results than other conventional therapies, is expected to drive the Tay-Sachs disease market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the Tay-Sachs disease market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for Tay-Sachs disease and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Tay-Sachs disease market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the Tay-Sachs disease market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the Tay-Sachs disease market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current Tay-Sachs disease marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Key Questions Answered in this Report:
Market Insights
How has the Tay-Sachs disease market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the Tay-Sachs disease market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the Tay-Sachs disease market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (?2018-2034?) of Tay-Sachs disease across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of Tay-Sachs disease by age across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of Tay-Sachs disease by gender across the seven major markets?
How many patients are diagnosed (?2018-2034?) with Tay-Sachs disease across the seven major markets?
What is the size of the Tay-Sachs disease patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of Tay-Sachs disease?
What will be the growth rate of patients across the seven major markets?
Tay-Sachs Disease: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for Tay-Sachs disease drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Tay-Sachs disease market?
What are the key regulatory events related to the Tay-Sachs disease market?
What is the structure of clinical trial landscape by status related to the Tay-Sachs disease market?
What is the structure of clinical trial landscape by phase related to the Tay-Sachs disease market?
What is the structure of clinical trial landscape by route of administration related to the Tay-Sachs disease market?
The Tay-Sachs disease market has been comprehensively analyzed in IMARC's new report titled "Tay-Sachs Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Tay-Sachs disease refers to a rare genetic disorder that primarily affects the nervous system. It is caused by a deficiency in the hexosaminidase A enzyme, which leads to the accumulation of a fatty substance called GM2 ganglioside in the nerve cells of the spinal cord and brain. The symptoms of this condition typically appear in the first few months of life and progress rapidly. Infants suffering from Tay-Sachs disease may experience developmental delays, progressive weakness, loss of muscle tone, an exaggerated startle response to sudden noises, an inability to move their eyes, etc. Numerous other common indications of the ailment may include seizures, difficulty swallowing, and, eventually, a loss of vision and hearing. The diagnosis of this illness requires a combination of the patient's clinical features, medical and family history, along with a physical and eye examination. A healthcare provider may also perform genetic testing to determine changes in the genome responsible for underlying symptoms. Furthermore, several blood workups to check the hexosaminidase A enzyme levels in the blood are recommended.
The rising incidences of DNA alterations, gene abnormalities, and chromosomal damage due to inherited disorders are primarily driving the Tay-Sachs disease market. Moreover, the widespread adoption of effective drugs, such as anti-seizures and antibiotics, to ease the symptoms and prevent the progression of the ailment is also augmenting the market growth. Apart from this, the inflating utilization of prenatal testing for Tay-Sachs disease through chorionic villi sampling or amniocentesis, which can reveal gene mutations associated with the condition and facilitate early detection in patients, is further creating a positive outlook for the market. Additionally, the escalating demand for occupational and physical therapies, owing to their numerous benefits like maintained joint flexibility, enhanced range of motion, delayed loss of muscular functions, improved daily activities, etc., is acting as another significant growth-inducing factor. Besides this, the growing popularity of gene therapy, that aims at permanent correction of the genetic defect, thereby allowing more effective and long-lasting therapeutic results than other conventional therapies, is expected to drive the Tay-Sachs disease market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the Tay-Sachs disease market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for Tay-Sachs disease and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Tay-Sachs disease market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the Tay-Sachs disease market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the Tay-Sachs disease market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current Tay-Sachs disease marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Key Questions Answered in this Report:
Market Insights
How has the Tay-Sachs disease market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the Tay-Sachs disease market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the Tay-Sachs disease market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (?2018-2034?) of Tay-Sachs disease across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of Tay-Sachs disease by age across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of Tay-Sachs disease by gender across the seven major markets?
How many patients are diagnosed (?2018-2034?) with Tay-Sachs disease across the seven major markets?
What is the size of the Tay-Sachs disease patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of Tay-Sachs disease?
What will be the growth rate of patients across the seven major markets?
Tay-Sachs Disease: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for Tay-Sachs disease drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Tay-Sachs disease market?
What are the key regulatory events related to the Tay-Sachs disease market?
What is the structure of clinical trial landscape by status related to the Tay-Sachs disease market?
What is the structure of clinical trial landscape by phase related to the Tay-Sachs disease market?
What is the structure of clinical trial landscape by route of administration related to the Tay-Sachs disease market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 TAY-SACHS DISEASE - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 TAY-SACHS DISEASE - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 TAY-SACHS DISEASE - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 TAY-SACHS DISEASE - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 TAY-SACHS DISEASE - UNMET NEEDS
10 TAY-SACHS DISEASE - KEY ENDPOINTS OF TREATMENT
11 TAY-SACHS DISEASE - MARKETED PRODUCTS
11.1 List of Tay-Sachs Disease Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 TAY-SACHS DISEASE - PIPELINE DRUGS
12.1 List of Tay-Sachs Disease Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name – Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13. TAY-SACHS DISEASE - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. TAY-SACHS DISEASE – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 TAY-SACHS DISEASE - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Tay-Sachs Disease - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Tay-Sachs Disease - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Tay-Sachs Disease - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Tay-Sachs Disease - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Tay-Sachs Disease - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Tay-Sachs Disease - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Tay-Sachs Disease - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Tay-Sachs Disease - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Tay-Sachs Disease - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Tay-Sachs Disease - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Tay-Sachs Disease - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Tay-Sachs Disease - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Tay-Sachs Disease - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Tay-Sachs Disease - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Tay-Sachs Disease - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Tay-Sachs Disease - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Tay-Sachs Disease - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Tay-Sachs Disease - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Tay-Sachs Disease - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Tay-Sachs Disease - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Tay-Sachs Disease - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Tay-Sachs Disease - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Tay-Sachs Disease - Access and Reimbursement Overview
16 TAY-SACHS DISEASE - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 TAY-SACHS DISEASE MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 TAY-SACHS DISEASE MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 TAY-SACHS DISEASE - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 TAY-SACHS DISEASE - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 TAY-SACHS DISEASE - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 TAY-SACHS DISEASE - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 TAY-SACHS DISEASE - UNMET NEEDS
10 TAY-SACHS DISEASE - KEY ENDPOINTS OF TREATMENT
11 TAY-SACHS DISEASE - MARKETED PRODUCTS
11.1 List of Tay-Sachs Disease Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 TAY-SACHS DISEASE - PIPELINE DRUGS
12.1 List of Tay-Sachs Disease Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name – Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13. TAY-SACHS DISEASE - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. TAY-SACHS DISEASE – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 TAY-SACHS DISEASE - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Tay-Sachs Disease - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Tay-Sachs Disease - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Tay-Sachs Disease - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Tay-Sachs Disease - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Tay-Sachs Disease - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Tay-Sachs Disease - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Tay-Sachs Disease - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Tay-Sachs Disease - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Tay-Sachs Disease - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Tay-Sachs Disease - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Tay-Sachs Disease - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Tay-Sachs Disease - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Tay-Sachs Disease - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Tay-Sachs Disease - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Tay-Sachs Disease - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Tay-Sachs Disease - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Tay-Sachs Disease - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Tay-Sachs Disease - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Tay-Sachs Disease - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Tay-Sachs Disease - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Tay-Sachs Disease - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Tay-Sachs Disease - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Tay-Sachs Disease - Access and Reimbursement Overview
16 TAY-SACHS DISEASE - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 TAY-SACHS DISEASE MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 TAY-SACHS DISEASE MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
